Article The Immunogenicity of Capsid-Like Particle Vaccines in Combination with Different Adjuvants Using Different Routes of Administration Christoph M. Janitzek 1,2, Philip H. R. Carlsen 1,2, Susan Thrane 1,2, Vijansh M. Khanna 1,2, Virginie Jakob 3, Christophe Barnier-Quer 4, Nicolas Collin 4, Thor G. Theander 1,2, Ali Salanti 1,2, Morten A. Nielsen 1,2 and Adam F. Sander 1,2,* 1 Centre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, 1165 København, Denmark;
[email protected] (C.M.J.);
[email protected] (P.H.R.C.);
[email protected] (S.T.);
[email protected] (V.M.K.);
[email protected] (T.G.T.);
[email protected] (A.S.);
[email protected] (M.A.N.) 2 Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark 3 Vaccine Formulation Institute, Plan-Les-Ouates, 1228 Geneva, Switzerland;
[email protected] 4 Vaccine Formulation Laboratory, University of Lausanne, 1015 Lausanne, Switzerland;
[email protected] (C.B.-Q.);
[email protected] (N.C.) * Correspondence:
[email protected]; Tel.: +45-30111529 Abstract: Capsid-like particle (CLP) displays can be used to enhance the immunogenicity of vaccine antigens, but a better understanding of how CLP vaccines are best formulated and delivered is needed. Citation: Janitzek, C.M.; Carlsen, This study compared the humoral immune responses in mice elicited against two different vaccine P.H.R.; Thrane, S.; Khanna, V.M.; antigens (a bacterial protein and a viral peptide) delivered on an AP205 CLP platform using six differ- Jakob, V.; Barnier-Quer, C.; Collin, N.; ent adjuvant formulations.